Prelude Capital Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-639,885
| Closed | -$9.25M | – | 1339 |
|
|
2026
Q1 | $9.25M | Buy |
639,885
+290,471
| +83% | +$4.16M | 0.71% | 20 |
|
|
2025
Q4 | $4.98M | Buy |
+349,414
| New | +$3.43M | 0.37% | 42 |
|
|
2021
Q4 | – | Sell |
-13,300
| Closed | -$127K | – | 2060 |
|
|
2021
Q3 | $127K | Hold |
13,300
| – | – | ﹤0.01% | 1466 |
|
|
2021
Q2 | $128K | Hold |
13,300
| – | – | ﹤0.01% | 1436 |
|
|
2021
Q1 | $131K | Sell |
13,300
-16,408
| -55% | -$254K | ﹤0.01% | 1392 |
|
|
2020
Q4 | $686K | Sell |
29,708
-5,348
| -15% | -$109K | 0.02% | 605 |
|
|
2020
Q3 | $495K | Sell |
35,056
-7,616
| -18% | -$111K | 0.02% | 446 |
|
|
2020
Q2 | $643K | Buy |
+42,672
| New | +$520K | 0.04% | 411 |
|
|
2019
Q4 | – | Sell |
-1,820
| Closed | -$15K | – | 2023 |
|
|
2019
Q3 | $15K | Buy |
+1,820
| New | +$19.8K | ﹤0.01% | 1434 |
|
|
2019
Q2 | – | Sell |
-584
| Closed | -$8K | – | 1818 |
|
|
2019
Q1 | $8K | Buy |
+584
| New | +$7.13K | ﹤0.01% | 1510 |
|
|
2018
Q4 | – | Sell |
-158,281
| Closed | -$1.74M | – | 1899 |
|
|
2018
Q3 | $1.91M | Buy |
158,281
+80,200
| +103% | +$1.12M | 0.11% | 205 |
|
|
2018
Q2 | $1.22M | Sell |
78,081
-49,618
| -39% | -$750K | 0.08% | 281 |
|
|
2018
Q1 | $1.92M | Buy |
127,699
+78,851
| +161% | +$1.2M | 0.14% | 128 |
|
|
2017
Q4 | $703K | Sell |
48,848
-23,952
| -33% | -$329K | 0.06% | 331 |
|
|
2017
Q3 | $1.1M | Sell |
72,800
-209,899
| -74% | -$2.78M | 0.1% | 228 |
|
|
2017
Q2 | $2.85M | Sell |
282,699
-31,170
| -10% | -$251K | 0.27% | 75 |
|
|
2017
Q1 | $2.24M | Sell |
313,869
-12,587
| -4% | -$79.6K | 0.21% | 114 |
|
|
2016
Q4 | $1.62M | Buy |
326,456
+65,146
| +25% | +$451K | 0.2% | 136 |
|
|
2016
Q3 | $1.93M | Buy |
261,310
+255,610
| +4,484% | +$1.73M | 0.2% | 102 |
|
|
2016
Q2 | $31K | Buy |
+5,700
| New | +$39.9K | ﹤0.01% | 1156 |
|
|
2016
Q1 | – | Sell |
-6,800
| Closed | -$48.2K | – | 1340 |
|
|
2015
Q4 | $66K | Sell |
6,800
-3,200
| -32% | -$28.8K | 0.01% | 960 |
|
|
2015
Q3 | $140K | Buy |
10,000
+5,500
| +122% | +$86.3K | 0.02% | 736 |
|
|
2015
Q2 | $64K | Buy |
+4,500
| New | +$54.1K | 0.01% | 1060 |
|
|
2015
Q1 | – | Sell |
-3,500
| Closed | -$30.9K | – | 2005 |
|
|
2014
Q4 | $29K | Sell |
3,500
-2,000
| -36% | -$13.7K | ﹤0.01% | 1633 |
|
|
2014
Q3 | $33K | Buy |
+5,500
| New | +$28.8K | ﹤0.01% | 1597 |
|
Other funds holding FOLD
Prelude Capital Management's FOLD Position: Q2 2026 in Review
Prelude Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 639,885 shares — an estimated $9.25M sold.
Prelude Capital Management first reported a position in FOLD in Q3 2014 and held it in 25 quarters. The position peaked at $9.25M in Q1 2026. 2 funds tracked by Wall St. Rank hold FOLD as of Q2 2026.
- Prelude Capital Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Prelude Capital Management sold 639,885 Amicus Therapeutics shares in Q2 2026, an estimated $9.25M.
- Prelude Capital Management first reported a position in Amicus Therapeutics in Q3 2014 and held it in 25 quarters.
- Prelude Capital Management's Amicus Therapeutics position peaked at $9.25M in Q1 2026.
- 2 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.